Navigation Links
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Date:3/16/2009

we and Pfizer elect to pursue that option.
  • Plan to initiate enrollment next month in our Phase 3 CONCERT trial, a 12-month safety and efficacy study evaluating Dimebon in combination with donepezil (Aricept(R)) in approximately 1,000 patients with mild-to-moderate Alzheimer's disease.
  • Plan to initiate two additional Phase 3 studies in 2009 that will evaluate Dimebon in a total of approximately 1,100 patients with moderate-to-severe Alzheimer's disease.
  • Huntington's Disease

    • Held an end-of-Phase 2 meeting at which the U.S. Food and Drug Administration (FDA) informed us that we could begin a Phase 3 trial of Dimebon in patients with Huntington's disease using the Mini-Mental State Examination (MMSE) and the Clinician's Interview-based Impression of Change, plus caregiver input (CIBIC-plus) as co-primary endpoints. Discussions with the European regulators are ongoing. We expect to begin this study in 2009.
    • Presented the data from the Phase 2 trial of Dimebon in Huntington's disease patients at the 9th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) held last week. Results showed Dimebon to be well tolerated and to significantly improve cognition as measured by the MMSE.

    Mechanism of Action (MOA)

    • Presented new data at various medical conferences, including the recent AD/PD conference, that provide additional evidence that Dimebon potentially stabilizes and improves mitochondrial function in a way that prevents neuron death and dysfunction, a mechanism thought to be distinct from currently available Alzheimer's disease medications.
    • At AD/PD, we presented new research from the Karolinska Institutet, which quantified the impact of Dimebon on mitochondrial function. Responses were seen on mitochondria
      '/>"/>

    SOURCE Medivation, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
    2. Medivation Presents New Data on Dimebons Novel Mechanism of Action
    3. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
    4. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
    5. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
    6. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
    7. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
    8. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
    9. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
    10. Medivation Announces Participation in Upcoming Conferences
    11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
    (Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
    (Date:7/10/2014)... 2014 Terascala, the industry leader in ... Swahn, a former vice president of product management for ... president of marketing. Terascala’s software when combined with leading ... the highest performance and most reliable solutions for processing ... Terascala’s channel expansion and broaden its product portfolio. His ...
    (Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
    Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
    ... Terrorist organizations sometimes have an advantage in the media. ... University of Haifa, published in the journal of Israel,s ... the advantage in this arena too. , ... against terrorist organizations, sometimes more so than conventional weapons. ...
    ... to strengthen its European business OFFENBACH MAIN, Germany, May ... Ltd., a leading multinational full service Contract Research Organization ... as President Strategic Operations Europe. Mr. Spector will be ... Mediation . Mr. Spector brings to Omega Mediation more ...
    ... Enfant(TM) Pediatric VEP Vision Testing System, Providing Early Detection ... If your child had vision problems, you,d be able ... Goldman, M.D., pediatrician at Children,s Health Center in Gurnee."Children ... deficits, even those they,ve had since birth," says Dr. ...
    Cached Biology Technology:Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2SIRO Group Appoints Scott L. Spector as President, Strategic Operations, for its European Business 2Chicago-Area Pediatricians Offering Unique Test to Detect Vision Problems in Children as Young as Six Months of Age 2
    (Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
    (Date:7/11/2014)... to the hippocampus, the marginal division of the ... What is the impact degree of substance P ... memory function? Yan Yu and his team, College ... using immunofluorescence staining, that substance P receptor, neurokinin ... striatal marginal division of normal rats. Unilateral or ...
    (Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
    Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
    ... 2009 The Center for Stem Cell & Regenerative Medicine ... Clinic (CC), University Hospitals (UH), and Athersys, Inc. has ... the Research Commercialization Program. The funding will help support ... four emerging and three pilot projects. This funding will ...
    ... scientists from Europe and China have gathered in Barcelona this ... research projects using data from ESA and Chinese Earth observation ... and the Ministry of Science and Technology (MOST) of China ... monitor and understand environmental phenomena in China. ,The symposium, held ...
    ... Although every cell in the body carries the genes ... small proportion of stem cells mature into those important immune-system ... Health and his colleagues have identified two "molecular motors" that ... cells. They published their findings June 19 in the online ...
    Cached Biology News:CWRU receives $5 million from Ohio Third Frontier Commission 2CWRU receives $5 million from Ohio Third Frontier Commission 3Europe and China watching Earth together 2Pushmi-pullyu of B-cell development discovered 2
    ...
    For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
    NATIVE, ENZYME PORCINE TRYPSIN...
    G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
    Biology Products: